<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476424</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 081</org_study_id>
    <nct_id>NCT00476424</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects</brief_title>
  <official_title>A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pharmacokinetic study of once daily Efavirenz 400 mg versus 600 mg in Thai HIV-1 infected&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efavirenz Pharmacokinetic evaluation supports once-daily dosing (T1/2 is 10-52 hours). The&#xD;
      recommended dosage of efavirenz in combination with nucleoside reverse transcriptase&#xD;
      inhibitor (NRTI) and/or protease inhibitor (PI) is 600mg orally, once daily.&#xD;
&#xD;
      In Thai populations, many ARV levels are very high. We believe that 600 mg efavirenz is too&#xD;
      high for Thai people and would like to see the pharmacokinetic data and safety and efficacy&#xD;
      of efavirenz at 400 mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess whether the low dose efavirenz is not inferior to the standard dose of efavirenz in terms of plasma concentration</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Access efavirenz plasma level after discontinuation of this medication</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg EFV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg EFV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years of age or older with HIV-1 infection&#xD;
&#xD;
          -  Who are on stable PI-based highly active antiretroviral therapy and have HIV-1 RNA &lt;50&#xD;
             copies/ml within 6 months.&#xD;
&#xD;
          -  No active opportunistic infection.&#xD;
&#xD;
          -  Sexually active subjects must be willing to use an effective form of birth control.&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding females are excluded.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
          -  ALT/ AST more than 5x upper limit&#xD;
&#xD;
          -  Relevant history or current condition, illness that might interfere with drug&#xD;
             absorption, distribution, metabolism or excretion.&#xD;
&#xD;
          -  Use of concomitant medication that may interfere with the pharmacokinetics of efavienz&#xD;
&#xD;
          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds which&#xD;
             may be employed in the study.&#xD;
&#xD;
          -  Active drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>once daily Efavirenz 400 mg</keyword>
  <keyword>PK once daily Efavirenz 400 mg versus 600 mg</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

